Navigation Links
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, PNT2258, has successfully demonstrated preclinical in vivo efficacy in xenograft mice for a number of human cancers - including curative events for difficult-to-treat Burkitt's Lymphoma.

Dr. Richard D. Gill, President and CEO of ProNAi, said, "Team ProNAi is quite pleased with our early preclinical results for PNT2258. Particularly encouraging is the fact that PNT2258 has shown promising single agent efficacy and combination therapy efficacy and drug-dose response for multiple cancer types including both hematological and solid tumors."

He added, "However, a very exciting development was our discovery that PNT2258, in combination with Rituximab, demonstrated curative events in treating Daudi xenografts of human Burkitt's Lymphoma in mice. The antitumor effect was rapid and durable. We had 70% complete remissions in two groups of animals dosed with PNT2258 and Rituximab."

In developing its DNAi(R)-based therapy, ProNAi reports that its successful establishment of in vivo efficacy for formulated PNT2258 included:

-- Single agent efficacy for DLCL2 Xenografts of Human Non-Hodgkin's Lymphoma

-- Combination therapy efficacy with Docetaxel for Human Hormone Refractory Prostate Cancer Xenograft

-- Combination therapy with Rituximab in Daudi Xenografts of Human Burkitt's Lymphoma

ProNAi's preclinical research will proceed in 2007. Planned studies include IND-enabling toxicology and ADME studies. ProNAi will file the IND for PNT2258 later this year.

About DNAi(R)

DNAi(R) (DNA interference) is a novel approach to targeting genomic DNA using sequence-specific therapeutic oligonucleotides, employing single strands of DNA to target
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/30/2015)... , June 30, 2015 Pulse Light ... a survey to Rosacea sufferers as part of their ongoing ... Rosacea sufferers found effective for their Rosacea. The survey participants ... comprised 47% men and 53% women. The results ... participants did not consider or attempt to visit their GP ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that the ... 14, 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an ... compound, tenapanor, which has completed Phase 2b clinical trials ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... MECHANICSBURG, Pa., Oct. 26, 2011 One out of three ... according to an Opinion Research/Select Medical telephone poll. Against that ... a statement today reminding the American public that influenza season ... chronic lung disease such as asthma or COPD (Chronic Obstructive ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year 2
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... its new YouTube video, “Fireside Convalescent Care Center.” The video informs community members ... video after continually seeing the need for those seeking care to be well ...
(Date:6/30/2015)... California (PRWEB) , ... June 30, 2015 , ... The ... Power today at a media event in San Diego. Speakers and clean air advocates ... School of medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder and president ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... On ... Have Acne ,” listed five triggers that most people would not expect to ... care products, and toothpaste. The primary causes of acne are clogged pores ...
(Date:6/30/2015)... ... June 30, 2015 , ... The progress of ... multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, ... to the Court’s calendar, that conference has now been scheduled for July 9th, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The U.S. Women's National Soccer Team will face the ... match will be on Sunday, August 16th at Heinz Field in Pittsburgh at 1:30 p.m. ... at Finley Stadium in Chattanooga, TN. , The USA WNT previously played at Heinz Field ...
Breaking Medicine News(10 mins):Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:USA vs. Costa Rica Tickets at Heinz Field in Pittsburgh and Finley Stadium in Chattanooga: Ticket Down Slashes Presale Ticket Prices for Costa Rica vs. USA WNT 2
... Center have performed the first complete genomic sequencing of ... lead to personalized treatments based on the unique biological ... may unveil new molecular targets for which more effective ... study also may lead to new and better ways ...
... , DENVER , Jan. 28 ... that it has entered into an agreement to acquire Highlands ... in the Denver suburb of Highlands Ranch ... the satisfaction of other requirements as detailed in the agreement. ...
... , ... Society of Hematology (ASH) now offers physicians who diagnose and ... education (CME) credits while staying abreast of the latest clinical ... partnership with Medscape, an online network of medical content for ...
... blood cells known as T cells differentiate into cells that fight ... of these "effector" T cells survive and become memory T cells, ... next time around. Scientists have identified a molecule that defines ... few days after a viral infection begins. The finding could guide ...
... ... disaster hit , ... (Vocus) January 28, 2010 -- When a devastating earthquake rocked a vulnerable Haiti on January ... rocked too. For years, American Podiatric Medical Association (APMA) doctors have travelled ...
... in what triggers jealousy in men and women, study finds ... in the eye of the beholder, a new study suggests. ... to men while emotional infidelity may be of greater concern ... experiences in previous relationships may be even more important. , ...
Cached Medicine News:Health News:UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line 2Health News:UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line 3Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 2Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 3Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 4Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 3Health News:Immune memory formation seen in early stages of viral infection 2Health News:American Podiatric Medical Association Podiatrists Perform Life-Saving Amputations in Haiti 2Health News:American Podiatric Medical Association Podiatrists Perform Life-Saving Amputations in Haiti 3Health News:Personal History Linked to Feelings of Betrayal 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: